SEC Tracker
Get the app

10-QKROS

Keros Therapeutics reported $40.01 million revenue for Q3 2026

The financial statements show that as of September 30, 2026, Keros had $259,464 thousand in cash and cash equivalents.1

By SEC Tracker ·

Keros TherapeuticsCIK 1664710Form 10-QFiled Nov 5, 2026, 4:04 PM ET0001664710-26-000066Read the filing on SEC.gov →

Its total assets were $307,371 thousand, and total liabilities were $28,273 thousand.2 The company reported a net income of $14,153 thousand for the three months ended September 30, 2026.3

Key facts

Company
Keros Therapeutics (KROS)
CIK
1664710
Form
10-Q
Filed
Nov 5, 2026, 4:04 PM ET
Accession
0001664710-26-000066

From the EDGAR filing index, not written by AI.

Keros Therapeutics results from its filings

Revenue, net income and cash as tagged in XBRL in the company's 10-Q and 10-K filings, up to this filing. Drawn in code; no figure here is written by AI.

Keros Therapeutics revenue and net income by quarterRevenueNet income$ millionsSource: XBRL in the company's 10-Q and 10-K filings, SEC EDGAR−50050100150200250Revenue · Q1 FY25: 211.2211.2Net income · Q1 FY25: 148.5148.5Revenue · Q2 FY25: 18.218.2Net income · Q2 FY25: −30.7−30.7Revenue · Q3 FY25: 14.314.3Net income · Q3 FY25: −7.3−7.3Revenue · Q1 FY26: 0.40.4Net income · Q1 FY26: −23.7−23.7Net income · Q2 FY26: −28.7−28.7Revenue · Q3 FY26: 40.040.0Net income · Q3 FY26: 14.214.2Q1 FY25Q2 FY25Q3 FY25Q1 FY26Q2 FY26Q3 FY26
Keros Therapeutics cash at period end$ millionsSource: XBRL in the company's 10-Q and 10-K filings, SEC EDGAR0200400600800259.5FY24Q1 FY25Q2 FY25Q3 FY25FY25Q1 FY26Q2 FY26Q3 FY26Cash · FY24: 559.9Cash · Q1 FY25: 720.5Cash · Q2 FY25: 690.2Cash · Q3 FY25: 693.5Cash · FY25: 287.4Cash · Q1 FY26: 281.5Cash · Q2 FY26: 257.6Cash · Q3 FY26: 259.5
The numbers
PeriodRevenueNet incomeCashFiling
FY24$3.6M−$187.4M$559.9M10-K
Q1 FY25$211.2M$148.5M$720.5M10-Q
Q2 FY25$18.2M−$30.7M$690.2M10-Q
Q3 FY25$14.3M−$7.3M$693.5M10-Q
FY25$244.1M$87.0M$287.4M10-K
Q1 FY26$0.4M−$23.7M$281.5M10-Q
Q2 FY26$0.0M−$28.7M$257.6M10-Q
Q3 FY26$40.0M$14.2M$259.5M10-Q

How often Keros Therapeutics files

Filings per calendar quarter, counted in code from the company's EDGAR filing list. Each bar splits 8-K current reports from other forms; the last bar is the quarter of this filing, counted up to it.

Keros Therapeutics filings per quarter8-KOther formsSource: EDGAR filing list, counted in code010203040508-K · Q1 25: 8Other forms · Q1 25: 88-K · Q2 25: 7Other forms · Q2 25: 348-K · Q3 25: 7Other forms · Q3 25: 68-K · Q4 25: 2Other forms · Q4 25: 158-K · Q1 26: 6Other forms · Q1 26: 228-K · Q2 26: 4Other forms · Q2 26: 238-K · Q3 26: 7Other forms · Q3 26: 168-K · Q4 26: 2Other forms · Q4 26: 2164113172827234Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26
Keros Therapeutics filings per quarter
The numbers
QuarterFilings8-K
Q1 25168
Q2 25417
Q3 25137
Q4 25172
Q1 26286
Q2 26274
Q3 26237
Q4 2642

Timeline

The company's filings on EDGAR around this one, newest first. Ownership forms and routine prospectus filings are left out.

  1. Form 10-QThis filing
  2. Form 8-K
  3. Form 8-K
  4. Form 8-K
  5. Form 8-K
  6. Form EFFECT

Get an email when Keros Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Written with AI from the Keros Therapeutics Form 10-Q and checked against it sentence by sentence: each of the 3 numbered sentences opens the passage it comes from. AI can make mistakes. Check the filing. Not investment advice. Not affiliated with the U.S. SEC. Source filing on SEC.gov.

Data on this page was fetched . The filing on SEC.gov is the record.